|Podcasts|July 16, 2013
What does RBM mean to Sanofi's CRAs and site monitors
Lori Convy, Assistant Director, Clinical Research Monitoring, Sanofi discusses what risk-based monitoring mean to Sanofi's CRAs and site monitors?
Advertisement
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE SummitFebruary 7th 2025
The MDR: Navigating Europe’s New Standard for Medical Device SafetyOctober 25th 2022
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
How Recent Policy Changes Could Impact Clinical Research
3
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
4
How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
